Browse by Series:

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

Francisco Esteva, MD, PhD
Published: Monday, Jul 02, 2018



Francisco Esteva, MD, PhD, director, breast medical oncology program, NYU Langone’s Perlmutter Cancer Center, highlights endocrine therapy plus CDK4/6 inhibitors for estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Findings from the MONALEESA-3 trial were presented at the 2018 ASCO Annual Meeting.

MONALEESA-3, a study conducted in nearly 730 patients, was called unique by Esteva because eligible patients were treated in the frontline setting without any prior hormone therapy or chemotherapy. The trial tested the clinical efficacy of ribociclib (Kisqali) and fulvestrant (Faslodex) compared with fulvestrant alone in the first- or second-line setting of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Patients received 600 mg/day of ribociclib on a 3-week on, 1-week off schedule. All patients also received fulvestrant 500 mg/day. Esteva says that this was the first study showing a significant increase in overall survival with a CDK4/6 inhibitor paired with fulvestrant in the frontline setting.

Esteva also shed light on encouraging phase II data with sacituzumab govitecan in ER-positive breast cancer, immunotherapy, and the phase III TAILORx trial, which focused on less chemotherapy in the adjuvant setting for select patients with breast cancer.

He adds that because of further research, chemotherapy should only be given to patients with high-risk breast cancer, while patients with low or intermediate risk should be treated with endocrine therapy alone.
Slider Left
Slider Right


Francisco Esteva, MD, PhD, director, breast medical oncology program, NYU Langone’s Perlmutter Cancer Center, highlights endocrine therapy plus CDK4/6 inhibitors for estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Findings from the MONALEESA-3 trial were presented at the 2018 ASCO Annual Meeting.

MONALEESA-3, a study conducted in nearly 730 patients, was called unique by Esteva because eligible patients were treated in the frontline setting without any prior hormone therapy or chemotherapy. The trial tested the clinical efficacy of ribociclib (Kisqali) and fulvestrant (Faslodex) compared with fulvestrant alone in the first- or second-line setting of patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Patients received 600 mg/day of ribociclib on a 3-week on, 1-week off schedule. All patients also received fulvestrant 500 mg/day. Esteva says that this was the first study showing a significant increase in overall survival with a CDK4/6 inhibitor paired with fulvestrant in the frontline setting.

Esteva also shed light on encouraging phase II data with sacituzumab govitecan in ER-positive breast cancer, immunotherapy, and the phase III TAILORx trial, which focused on less chemotherapy in the adjuvant setting for select patients with breast cancer.

He adds that because of further research, chemotherapy should only be given to patients with high-risk breast cancer, while patients with low or intermediate risk should be treated with endocrine therapy alone.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x